ImmunityBio converts from Immunomedics | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
ImmunityBio converts from Immunomedics

An SI Board Since February 2023

Posts	SubjectMarks	Bans	Symbol
1504	51	0	IBRX

Emcee: TinfoilHat	Type: Moderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
979	Seems it’s long overdue that tinfoil gives his take on all of this.	galt	2	4/30/2025
978	This article published a few days ago could explain some of the recent post-equi	Maturin	2	4/30/2025
977	Apr 28, 2025 8:30 AM Eastern Daylight Time Unmatched Long-Term Bladder Preserva	zagnut1	3	4/28/2025
976	Without a big pharma partner the market for Anktiva is growing slower than the m	waitwatchwander	1	4/25/2025
975	I am starting to think that IBRX has a version of the “AUPH disease”. That is,	jargonweary	-	4/25/2025
974	That’s ok. I still hold GILD. Thanks for the update. They didn’t miss projection	dorightbythem	-	4/24/2025
973	Sorry I meant to post that on another site	jargonweary	-	4/24/2025
972	finance.yahoo.com	jargonweary	-	4/24/2025
971	Good questions but longer term the more important question may be- "What wi	mannamal	-	4/23/2025
970	The question now is: Will the combination of Tislelizumab (anti-PD-1) and Anktiv	Huggenberg	2	4/23/2025
969	finance.yahoo.com	mannamal	-	4/23/2025
968	I wonder if Tinfoil might give us his thoughts on the company, it’s leadership a	jargonweary	3	4/17/2025
967	Deleted, wrong thread.	waitwatchwander	-	4/16/2025
966	The 5 hour Investor's Day presentation reiterated a lot of information about	End2War	1	4/16/2025
965	I have a slight but still nagging concern that our pending drug approval in Euro	jargonweary	-	4/16/2025
964	HC Wainwright & Co. analyst Andres Maldonado reiterates ImmunityBio(IBRX) wi	luckydog88	-	4/16/2025
963	This is probably the only “blockbuster news”. It was published this morning. Im	Olecranon	-	4/15/2025
962	“Investor day is still ongoing fwiw...”. Ah, yes good point. I keep for	jargonweary	1	4/15/2025
961	Investor day is still ongoing fwiw...	erippetoe	-	4/15/2025
960	If so they must have been misled. Investor day turned out to be a big swing and	jargonweary	-	4/15/2025
959	Through question from audience member, PSS was basically saying the FDA was bloc	zagnut1	-	4/15/2025
958	BTW. They’re on a lunch break until 12:30 PM PST…	erippetoe	-	4/15/2025
957	Thanks! Retirement makes you lose track of days!	TripleE3	2	4/15/2025
956	Investor day is today and is in progress at cts.businesswire.com	erippetoe	1	4/15/2025
955	ImmunityBio(IBRX) also reported preliminary net product revenue of about $16.5 m	TripleE3	-	4/15/2025

Go to reply# or date (mm/dd/yy):